Kenvue Inc.
Financials
Valuation Metrics
Kenvue Inc.'s Market Cap is $36.48B. At end of 2025 it was $32.68B. Ranked #408 of 3,112 in US market (top 13%), #291 of 1,667 on NYSE (top 17%), #4 of 17 in Household & Personal Products (top 24%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $36.48B | US#408/3,112 Sec#4/17 |
| Revenue | $15.29B | US#416/3,112 Sec#5/17 |
| Net Income | $1.62B | US#376/3,112 Sec#5/17 |
| Total Assets | $26.85B | US#511/3,112 Sec#3/17 |
| Net Assets | $10.61B | US#404/3,112 Sec#3/17 |
| Employees | 21,780 | US#344/3,112 Sec#6/17 |
| Value | ||
| P/E | 22.49x | US#1,164/3,112 Sec#7/17 |
| P/B | 3.44x | US#1,825/3,112 Sec#8/17 |
| PEG | 0.48x | US#550/3,112 Sec#3/17 |
| P/S | 2.39x | US#1,454/3,112 Sec#11/17 |
| EV/EBITDA | 13.90x | US#1,331/3,112 Sec#8/17 |
| FCF Yield | 5.00% | US#1,277/3,112 Sec#9/17 |
| Profitability | ||
| ROE | 15.29% | US#853/3,112 Sec#6/17 |
| ROA | 6.04% | US#858/3,112 Sec#8/17 |
| Op. Margin | 19.62% | US#940/3,112 Sec#4/17 |
| Revenue Growth | 4.49% | US#1,794/3,112 Sec#7/17 |
| Earnings Growth | 47.20% | US#586/3,112 Sec#3/17 |
| Financial Health | ||
| Debt Ratio | 153.15% | US#1,526/3,112 Sec#9/17 |
| Total Debt | $8.66B | US#439/3,112 Sec#4/17 |
| FCF | $1.82B | US#373/3,112 Sec#5/17 |
| Cash | $1.07B | US#652/3,112 Sec#6/17 |
| Current Ratio | 0.98x | US#2,303/3,112 Sec#12/17 |
| Net Debt/EBITDA | 2.39x | US#1,489/3,112 Sec#8/17 |
| Dividend | ||
| Div. Yield | 6.50% | US#169/3,112 Sec#1/17 |
| Div. Growth | -89.71% | US—/3,112 Sec—/17 |
| Performance | ||
| 1Y Return | -9.00% | US#2,395/3,112 Sec#11/17 |
| 1M Return | -4.19% | US#2,157/3,112 Sec#14/17 |
| From 52W High | -11.58% | US#1,158/3,112 Sec#8/17 |
| 1Y MDD | -41.09% | US#1,993/3,112 Sec#8/17 |
| Trading | ||
| Volume | 22,050,150 shares | US#71/3,112 Sec#2/17 |
| Trading Value | $422M | US#248/3,112 Sec#4/17 |
| Per Share | ||
| EPS | $0.77 | US#1,718/3,112 Sec#11/17 |
| BPS | $5.62 | US#2,168/3,112 Sec#12/17 |
Company Info
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.